ARG1-D Is a rare inherited disease affecting growth, learning and health. Pegzilarginase has not previously been studied in patients below 2 years of age. Our patient recruited into the trial is receiving weekly treatment through the study at St Lukes hospital and hopefully it will have a substantial impact on the course of their disease . This in turn could then allow other patients below 2 years to be treated with the drug .
